DermaSensor
DermaSensor is a Miami-based medical device company that sells an FDA-cleared, AI-powered handheld device using Elastic Scattering Spectroscopy to help primary care physicians non-invasively assess suspicious skin lesions for melanoma, BCC, and SCC at the point of care via a monthly subscription.
- Company typePrivate
- Founded2009
- HeadquartersMiami, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What DermaSensor does
DermaSensor, Inc. is a Miami-based medical device company founded in 2009 that develops an FDA-cleared, AI-powered handheld device for non-invasive skin cancer risk assessment at the point of care. The device combines Elastic Scattering Spectroscopy (ESS) — an optical tissue-sampling technique exclusively licensed from Boston University — with a proprietary neural network machine learning algorithm trained on more than 20,000 spectral scans from 4,500+ histologically confirmed skin lesions. It delivers a binary "Investigate Further" or "Monitor" result plus a 1-10 malignancy confidence score in seconds, with 96% sensitivity for melanoma, basal cell carcinoma, and squamous cell carcinoma in pivotal studies. The product is the first FDA-cleared automated device indicated for all three common skin cancers and the first developed specifically for primary care physicians, who currently miss an estimated 18% of skin cancers due to subjective visual examination alone.
The company's commercial strategy targets the 300,000+ U.S. primary care physicians who see suspicious lesions but face 36.5-day average wait times for dermatology referrals. DermaSensor sells through a direct sales motion (demo requests, field sales targeting health systems and multi-site practices) on a subscription model with two tiers — $199/month for up to 5 patients and $399/month for unlimited users and scans — with no upfront capital cost, a 90-day risk-free trial, and bundled customer support, replacement devices, software updates, and cloud storage. Reimbursement friction is mitigated through a partnership with The Reimbursement Group (TRG) covering CPT codes 96999 and 17999. A Physician Finder directory drives patient-side demand. As of late 2025, the device is commercially available in Florida and Pennsylvania with a waitlist in other U.S. states, and the company holds a Class IIb CE Mark enabling European Economic Area commercialization via a recently signed large European distributor partner. DermaSensor has raised $43M in total funding, including a $16M Series B in October 2025, and is led by CEO Cody Simmons with co-founder/Chairman Dr. Maurice Ferre (former CEO of MAKO Surgical, sold to Stryker for $1.65B) and a Scientific Advisory Board that includes the original ESS inventor Dr. Irving Bigio and senior dermatology academic clinicians.
DermaSensor firmographics
Firmographics- Name
- DermaSensor
- Legal name
- DermaSensor, Inc.
- Website
- https://dermasensor.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DermaSensor is a Miami-based medical device company that sells an FDA-cleared, AI-powered handheld device using Elastic Scattering Spectroscopy to help primary care physicians non-invasively assess suspicious skin lesions for melanoma, BCC, and SCC at the point of care via a monthly subscription.
- Ownership category
- akta.pro rank
DermaSensor industry classification
Industry- Product category
- Medical Diagnostic Devices
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Dermatology Telemedicine Platforms (HLALAGAA)
Keywords
Where DermaSensor is headquartered
LocationHeadquarters
- HQ city
- Miami
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
DermaSensor business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- Device Subscription/Rental: Monthly subscription model for the DermaSensor device. Physicians pay recurring monthly fees to access the device, software, cloud storage, customer support, replacement devices, and software updates. No upfront capital cost; device remains property of DermaSensor.
- Professional Services - Reimbursement Support: Reimbursement guidance services provided through partnership with TRG (The Reimbursement Group) at no cost to customers. Billing support for CPT codes 96999 and 17999 for DermaSensor services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Basic tier - Up to 5 patients per month |
| Subscription | Monthly | Premium tier - Unlimited users and scans |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
DermaSensor product offering
Product offeringCore offering
DermaSensor develops, manufactures, and distributes an FDA-cleared, AI-powered handheld device that uses Elastic Scattering Spectroscopy (ESS) combined with a proprietary neural network machine learning algorithm to enable primary care physicians to non-invasively evaluate suspicious skin lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma at the point of care. The company sells the device through a monthly subscription model (with tiers at $199 and $399 per month) that includes software updates, cloud storage, replacement devices, customer support, and reimbursement guidance through a partnership with TRG.
Product overview
DermaSensor offers a single core product—the FDA-cleared DermaSensor handheld device for AI-powered skin cancer detection in primary care. The device uses Elastic Scattering Spectroscopy combined with a proprietary machine learning algorithm to provide immediate point-of-care risk assessment for melanoma, BCC, and SCC. Supporting services include a Physician Finder directory for patient referrals and reimbursement support through a partnership with TRG (The Reimbursement Group). The company is exploring future EHR integration and next-generation device features including a camera.
Differentiator
Problem solved
Functional benefit
Products and services
- DermaSensor Device FDA-cleared, AI-powered handheld skin cancer detection device using Elastic Scattering Spectroscopy to non-invasively evaluate suspicious lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma. Provides immediate point-of-care risk assessment with "Investigate Further" or "Monitor" output plus a 1-10 malignancy score, sold through monthly subscriptions to primary care physicians, health systems, and concierge practices.
- Physician Finder Directory Online directory enabling patients to locate healthcare providers who offer DermaSensor-based skin cancer evaluation, searchable by ZIP code, city, or state. Functions as a patient acquisition tool for subscribing physicians.
- Reimbursement Support via TRG Partnership Free reimbursement guidance service provided through partnership with The Reimbursement Group (TRG), including documentation assistance for government and private insurance plans and coding support for CPT codes 96999 and 17999. Bundled with DermaSensor device subscriptions.
Quantifiable outcome
- 96% sensitivity for detecting all three common skin cancers in pivotal clinical trials
- +11 more outcomes
Companies that use DermaSensor
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
DermaSensor technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
DermaSensor partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- UK National Health Service (NHS)flagshipFeasibility study collaboration with UK's National Health Service. Marks beginning of global expansion strategy and validates international clinical utility of DermaSensor's technology in single-payer healthcare system.
- TRG (The Reimbursement Group)corePartnership provides free reimbursement guidance to DermaSensor customers. TRG offers targeted support tailored to patient payer requirements, documentation help for government and private insurance plans, and coding guidance including CPT codes 96999 and 17999.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
DermaSensor competitors and assessment
Company assessmentDirect peers
- Verisante Technology: Canadian developer of the Verisante Aura, a Raman spectroscopy-based device for rapid skin lesion assessment. Uses optical spectroscopy analogous to DermaSensor's ESS approach, making it a technology analog and direct competitor in non-invasive skin cancer detection.
- Skin Analytics: UK-based AI dermatology company whose DERM autonomous skin cancer detection platform is used in NHS pathways. Most direct head-to-head competitor to DermaSensor, applying AI to triage suspicious lesions without requiring dermatologist review at the front line.
- Canfield Scientific: US leader in dermatology imaging systems (VECTRA, IntelliStudio) used for skin documentation and AI-assisted analysis. Established peer providing imaging infrastructure that overlaps with DermaSensor's point-of-care capture workflow.
- MetaOptima Technology: Developer of DermEngine, an AI dermatology imaging and analytics platform used by clinics and teledermatology services. Competes with DermaSensor in AI-assisted skin lesion evaluation, particularly in teledermatology workflows.
- DermTech: Public US company (DMTK) offering the DermTech Melanoma Test, an adhesive patch genomic assay for skin cancer risk. Closest US-listed peer working on non-invasive, point-of-care skin cancer detection with payer coverage.
- FotoFinder Systems: German maker of FotoFinder body mapping and AI mole analysis systems widely used by dermatologists. Closest established peer in AI-assisted dermoscopic imaging and total body photography for skin cancer detection.
- SkinVision: Smartphone-based AI skin lesion assessment app serving consumer and clinician segments across Europe and emerging markets. Directly competes on the AI skin cancer detection value proposition with a lower-cost, software-only delivery model.
Broad incumbents
- DermLite (3Gen): Incumbent dermoscopy device maker supplying handheld skin examination tools to dermatologists globally. Represents the established optical examination workflow that DermaSensor aims to supplement in primary care settings.
- Caliber Imaging & Diagnostics: Maker of VivaScope confocal microscopy systems for non-invasive cellular-level skin imaging in dermatology practices. Competes in advanced non-invasive skin lesion evaluation but operates in a higher-priced specialist niche rather than primary care.
Emerging players
- STRATA Skin Sciences: Successor to Mela Sciences (MelaFind), focused on dermatology devices and clinic services. Historically the most direct US skin cancer detection device analog and a useful comparator for the regulatory and reimbursement trajectory of such products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
DermaSensor social profiles
Digital presenceDermaSensor compliance and trust
Trust signalCompliance2 records
DermaSensor financial estimates
Financial estimateRevenue estimate
Valuation estimate
DermaSensor leadership team
Management profileNumber of profiles
Profiles15 records
DermaSensor subsidiaries and ownership
Company hierarchySubsidiaries2 records
DermaSensor funding detail
Funding detailFunding overview
Funding rounds11 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DermaSensor M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DermaSensor
What does DermaSensor do?
DermaSensor develops, manufactures, and distributes an FDA-cleared, AI-powered handheld device that uses Elastic Scattering Spectroscopy (ESS) combined with a proprietary neural network machine learning algorithm to enable primary care physicians to non-invasively evaluate suspicious skin lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma at the point of care. The company sells the device through a monthly subscription model (with tiers at $199 and $399 per month) that includes software updates, cloud storage, replacement devices, customer support, and reimbursement guidance through a partnership with TRG.
Is DermaSensor a public or private company?
DermaSensor is a private company. It is classified as venture growth investor backed and is currently operating.
When was DermaSensor founded?
DermaSensor was founded in 2009. It employs 11 to 50 people.
Where is DermaSensor based?
DermaSensor is headquartered in Miami, United States, in the North America region.
How does DermaSensor make money?
Two revenue lines are on record. Device Subscription/Rental is the primary driver. The others are professional Services - Reimbursement Support.
Who are DermaSensor's main competitors?
Direct peers on record are Verisante Technology, Skin Analytics, Canfield Scientific, MetaOptima Technology, DermTech, FotoFinder Systems and SkinVision. Broad incumbents are DermLite (3Gen) and Caliber Imaging & Diagnostics. STRATA Skin Sciences is listed as an emerging player.
Does DermaSensor have an API?
No public API is recorded for DermaSensor.
What industry is DermaSensor in?
DermaSensor's product category is Medical Diagnostic Devices. Its primary akta.pro industry code is HLALAGAA, Dermatology Telemedicine Platforms. Its NAICS code is 62151 and its SIC code is 3841.